In-practice Evaluation of Atacand 16mg Antihypertensive Effect

Essential Hypertension Clinical Trial

Official title:

In-practice Evaluation of Atacand 16mg Antihypertensive Effect

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00802542
• Other study ID #: NIS-CLV-ATA-2008/1
• Status: Completed
• Phase: N/A
• First received: December 4, 2008
• Last updated: December 2, 2010
• Start date: November 2008
• Est. completion date: January 2009

Study information

• Verified date: December 2010
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Health authority: Latvia: State Agency of Medicines
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to prove in practice the effectiveness of Atacand 16 mg in reducing blood pressure after 4 weeks of administration and the importance of administration of adequate doses

Recruitment information / eligibility

• Status: Completed
• Enrollment: 400
• Est. completion date: January 2009
• Est. primary completion date: January 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients with mild (140-159/90-99 mgHg) to moderate (160-179/100-109 mmHg) essential hypertension, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal at least <140/90 mgHg and the doctor has decided

• Signed and dated Patient Informed Consent (ICF)

Exclusion Criteria:

• Hypersensitivity to the active substance or to any of the excipients of Atacand.

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Essential Hypertension
• Hypertension

Locations

Country	Name	City	State
Latvia	Research site	Daugavpils
Latvia	Research site	Jelgava
Latvia	Research site	Liepaja
Latvia	Research Site	Riga

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Country where clinical trial is conducted

Latvia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Decrease in blood pressure		once after 4 weeks	No